Arzneimittelforschung 2007; 57(6): 339-346
DOI: 10.1055/s-0031-1296628
Antibiotics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Comparative Acute Systemic Toxicity of Several Quinoxaline 1,4-Di-N-oxides in Wistar Rats

Amaya Azqueta
1   Center of Research in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain
,
Ana Gloria Gil
1   Center of Research in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain
,
Alba García-Rodríguez
2   Department of Animal Pathology. Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain
,
Jose Antonio García-Jalón
2   Department of Animal Pathology. Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain
,
Felipe Cia
1   Center of Research in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain
,
Belén Zarranz
1   Center of Research in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain
,
Antonio Monge
1   Center of Research in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain
,
Adela López de-Cerain
1   Center of Research in Applied Pharmacobiology (CIFA), University of Navarra, Pamplona, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2011 (online)

Abstract

The acute toxicity of six quinoxaline 1,4-di-N-oxides has been evaluated in an attempt to determine: a) the feasibility of testing systemic toxicity of these compounds in a very preliminary phase without an adequate formulation for in vivo administration, b) the LD50 range and the toxic target organ of these compounds in order to have an approximation of the structure-activity relationship. Quinoxaline 1,4-di-N-oxides have shown a great variety of biological activities with potential therapeutic application in cancer, malaria, etc. Problems of toxicity hinder the progression of these compounds to clinical phases. The compounds dissolved in DMSO at their solubility limit were administered i.V. to female Wistar rats (8 weeks, 160 g), using an infusion pump (300 µL; 20 µl/min). Animals were observed for a period of 14 days. This dose of the vehicle (1.7 ml/kg) was well tolerated by the animals. The LD50 could not be determined, but a marked hypoactivity was induced by the treatment. The same compounds were also injected intraperi-toneally, suspended in 0.01 % Tween 80/0.09% saline, and the animals that did not die were observed for a period of 14 days. The LD50 could be estimated to be in a range between 30 and 120 mg/kg, except for one of the compounds. A decrease in the evolution of body weight and hypoactivity were the principal symptoms induced by the treatment. In both assays, histopathologic study of heart, liver, kidney, lung, spleen and ovaries indicated that the target organs may be heart and spleen. In conclusion, the i.V. route is not adequate for estimating the LD50 of these compounds due to solubility problems; by i.p. route, the LD50 interval is between 30 and 120 mg/kg. The data did not permit the deduction of any specific structure-activity relationship.